Product News: ChromoTek’s Fluorescent Two Hybrid (F2H®) Technology Enables Screening and Validation of Compounds in Living Cells

15 May 2013

ChromoTek GmbH (Munich, Germany) has developed a series of highly sensitive protein-protein interaction (PPI) assays to screen compounds that resolve the binding of two proteins within cells. The so called fluorescent two hybrid (F2H®) technology is based on a proprietary cell line that contains a spot-like landing platform where one interaction partner binds. The interacting proteins are tagged with different fluorescent proteins and co-localize to the same spot upon binding. The respective dual fluorescent bright merge signal is clearly detectable and measurable under the microscope. Disruption of the binding by test substances recreates a single fluorescent spot. For drug discovery campaigns the F2H® platform can be fully automated.

One particular advantage of the F2H® platform is that only those molecules will emerge as possible drug candidates which are taken up into cells and which show little or no cytotoxicity. In addition, due to the standardized binding platform used, it is possible to conduct comparative protein-protein interaction (PPI) studies.

To date, more than 50 protein-protein interactions have been successfully reconstructed with the F2H®system. "For example, by tracing the binding of p53 to Mdm2 or Mdm4, known inhibitors of these interactions could be verified and new inhibitors identified" states Dr. Kourosh Zolghadr, Head of R&D at ChromoTek. Further encouragement comes from ChromoTek's academic partner Prof. Sir David Lane who calls the F2H® approach a missing link between biochemistry and cell biology. In collaboration with his lab, the F2H® assay was successfully applied to do a comprehensive (stapled) peptide profiling for activation of p53 (recently published in ACS Chem. Biol. 8 (3): 506‐512 (2013)).
ChromoTek not only offers p53:Mdm2 and/or p53:Mdm4 compound screening and profiling services but, owing to the flexibility and versatility of this new technology, develops customized F2H® PPI assays to conduct compound screening services for biotech/Pharma partners aiming to increase the efficiency of their drug discovery and validation programs with real-time cellular data.